DOCSLIB.ORG

Clinical Characteristics of Pramipexole-Induced Peripheral Edema

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Characteristics of Pramipexole-Induced Peripheral Edema ORIGINAL CONTRIBUTION Clinical Characteristics of Pramipexole-Induced Peripheral Edema Eng-King Tan, MD; William Ondo, MD Background: Pramipexole, a new dopamine agonist, ef- (range, 0.25-11 months). The mean (±SD) dose at onset fectively treats early and advanced Parkinson disease and of PE was 1.7 ± 1.0 mg/d (dose range, 0.75-3 mg/d) and restless legs syndrome. the mean (±SD) dose when PE was at its maximum was 2.6 ± 0.7 mg/d (dose range, 1.5-3 mg/d). In all cases, the Objectives: To report the clinical features of and to in- PE rapidly abated with discontinuation of therapy, and vestigate the predisposing factors and eventual out- in all cases that we rechallenged, it rapidly returned. The comes in patients who developed peripheral edema (PE) condition seemed to be dose dependent but also idio- following treatment with pramipexole. syncratic, as we could not identify any predisposing fea- tures. It resulted in extensive medical evaluation in some Design: Retrospective case series in a tertiary referral patients and was only minimally responsive to diuretic center. therapy. Results: Of the 300 patients who were receiving pra- Conclusion: Peripheral edema should be included mipexole therapy, 17 patients had mild to severe PE, among the potential adverse events associated with pra- which was attributable to the medication. Fifteen pa- mipexole therapy. tients had Parkinson disease and 2 patients had restless legs syndrome. The mean (±SD) time of onset of PE af- ter pramipexole therapy was started was 2.6 ± 3.6 months Arch Neurol. 2000;57:729-732 RAMIPEXOLE, a new dopamine REPORT OF CASES agonist, has been shown to be an effective treatment of early CASE 1 and advanced Parkinson dis- ease (PD)1-7 and restless legs A 66-year-old woman (patient 6) had 8,9 Psyndrome. It is a potent agonist at the D2 symptoms of parkinsonism for 4 years. She dopamine-receptor group, with highest af- was initially started on a combined regi- 7,8,10,11 finity to D3 dopamine-receptors. Pra- men of levodopa/carbidopa and amanta- mipexole is usually well tolerated. Com- dine hydrochloride. Pramipexole therapy monly reported side effects include nausea, was added 1 year ago. She noticed some somnolence, and visual hallucinations.1-7 Re- ankle PE within 1 week of adding prami- cently, sleep attacks have also been re- pexole therapy. Nevertheless, she fol- ported.12 Peripheral edema (PE) as a side ef- lowed the dosing schedule and subse- fect of dopamine agonists, has been rarely quently increased to a maintenance dose reported with bromocriptine mesylate,13-16 of 3 mg/d. Pramipexole therapy im- ropinirole hydrochloride,17 and cabergo- proved PD, but the PE extended up to both line.16 However, this adverse effect is not of her knees resulting in discomfort and demonstrated in other studies.18-20 difficulty wearing her shoes. To our knowledge, PE has not been The results of an extensive evalua- shown to be significantly associated with tion including a 2-dimensional echocar- 1-6 From the Parkinson’s Disease pramipexole therapy. We describe the diogram, Doppler ultrasound of her lower Center and Movement clinical features and investigate possible extremities, and hepatic and liver func- Disorders Clinic, Department predisposing factors and eventual out- tion tests were unremarkable. The PE im- of Neurology, Baylor College comes in patients who developed PE af- proved only mildly with leg elevation and of Medicine, Houston, Tex. ter starting pramipexole therapy. furosemide therapy. Amantadine therapy ARCH NEUROL / VOL 57, MAY 2000 WWW.ARCHNEUROL.COM 729 ©2000 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 therapy of levodopa and selegiline hydrochloride. Bilat- eral ankle swelling was noticed about 3 weeks after ini- PATIENTS AND METHODS tiating pramipexole therapy, while taking 1.5 mg/d. He titrated up to 3 mg/d. The PE at the ankles increased in Of the 300 patients who were receiving pramipex- severity and progressed above both of his knees to the ole therapy and evaluated at our outpatient clinic, 17 midthigh. The severity of the PE limited his mobility and satisfied the following inclusion criteria and were en- caused significant distress. Treatment with diuretics gave rolled in this study: (1) taking pramipexole therapy only mild improvement in his condition. His liver and for parkinsonism or restless legs syndrome, (2) no renal function test results were within normal limits. He history of PE prior to initiation of pramipexole also underwent a series of cardiac studies the results of therapy, (3) development of PE while receiving pra- which were unremarkable. mipexole therapy and resolution or marked improve- After 1 year of receiving 3 mg/d pramipexole therapy ment of PE shortly after stopping the medication, and with persistent PE, he was instructed to taper the dos- (4) no clinical and biochemical evidence of renal, car- age and then discontinue taking the medication. Three diac, and hepatic failure. The following information was documented for days after discontinuing the drug, the PE completely re- patients who were enrolled in the study: (1) demo- solved. Because pramipexole therapy significantly im- graphics, (2) duration of disease, (3) total duration proved his PD symptoms, he restarted the drug. At 1.5 of pramipexole therapy, (4) duration of pramipex- mg/d, he noticed a gradual return of the PE at his ankles. ole therapy until the onset of PE, (5) dose of prami- The dose has not been increased, and the PE remains re- pexole per day when PE was at its worst, (6) sever- stricted to his ankles. ity of PE (ie, at the level of ankle, midshin, knee, thigh, or generalized), (7) functional disability, as mea- RESULTS sured by difficulty wearing shoes, walking, or exer- tional dyspnea, (8) outcome (either still receiving Seventeen patients (8 males) were studied, with a mean therapy or no longer receiving therapy), (9) history of other medication usage, (10) effects of rechal- (±SD) age of 63.8 ± 10.6 years (age range, 44-82 years). The lenge with pramipexole, and (11) potential dose re- mean (±SD) duration of PD was 7.3 ± 5.0 years (range, 2-28 sponse. years). Fifteen patients were treated for PD, 13 in Hoehn All study patients were asked to taper and then and Yahr stage II while receiving pramipexole therapy, and completely stop pramipexole therapy. Those pa- 2 in stage III. Two patients had restless legs syndrome. tients who found the drug to be effective for their dis- The mean (±SD) time of onset of PE after prami- ease symptoms, were given the choice to restart the pexole therapy was started was 2.6 ± 3.6 months (range, medication, after the PE had subsided. 0.25-11 months) (Table). The mean (±SD) dose at on- set of PE was 1.7 ± 1.0 mg/d (dose range, 0.75-3 mg/d) and the mean(±SD) dose when PE was maximum was 2.6 ± 0.7 mg/d (dose range, 1.5-3 mg/d)(Table). Seven was discontinued, as her internist thought this may be patients (41.2%) had PE restricted to the ankles, 5 (29.4%) culpable; however, there was no improvement in the PE. at the calves, and 5 (29.4%) at or above the knees. Six- At the time of our physical examination, she had teen patients (94.1%) reported difficulty wearing their moderate bradykinesia and rigidity in her extremities. Pit- shoes, and 13 (76.5%) had difficulty walking. No pa- ting PE of both her lower extremities were present up to tient had concurrent livedo reticularis or erythromyal- her knees, with thickening of overlying skin, indicating gia. All except 1 patient reported complete resolution of chronicity of the PE. There was no livedo reticularis or PE after the medication was stopped for a few days. The erythromylagia. She had no evidence of renal, hepatic, remaining patient had an 80% reduction of her PE. or cardiac failure. We instructed her to taper off the dos- Eleven patients (64.7%) decided to restart pramipexole age of pramipexole over a course of 1 week without ad- therapy, but at a lower dosage. Ten reported return of justing her levodopa dosage. One week after she was no the PE within 1 week, but to lesser severity, and 2 longer receiving pramipexole therapy, she reported at least patients discontinued use of the drug. an 80% improvement of her PE, and she was able to wear Other possible concurrent causes of PE included 2 pa- her usual shoes. As pramipexole therapy improved her tients with quiescent malignancy of the prostate and uterus, PD, and was otherwise well tolerated, she elected to re- and 1 patient with hypothyroidism. Three were receiving start pramipexole therapy, but at a lower dose of 0.75 amantadine therapy, and 2 were receiving a calcium an- mg/d. Within 2 weeks, she had noticed an increase of her tagonist. None of these patients had a history of PE. PE at her ankles, but to a lesser degree than before. She continued usage of pramipexole therapy at this dosage. COMMENT CASE 2 We report mild to severe PE in patients that is attribut- able to pramipexole therapy. In all cases, the PE rapidly A 60-year-old man (patient 11) has a 3-year history of abated within 1 week after discontinuation of the drug, PD, presently complicated by levodopa-induced dipha- and in all cases that we rechallenged with pramipexole sic dyskinesias and motor fluctuations. Pramipexole therapy, PE rapidly returned. The condition seemed to therapy, at an initial dose of 0.375 mg/d, was started be dose dependent but also idiosyncratic, as we could not 1 year ago.
Load more

Recommended publications
  • Dermatologic Manifestations and Complications of COVID-19
    American Journal of Emergency Medicine 38 (2020) 1715–1721 Contents lists available at ScienceDirect American Journal of Emergency Medicine journal homepage: www.elsevier.com/locate/ajem Dermatologic manifestations and complications of COVID-19 Michael Gottlieb, MD a,⁎,BritLong,MDb a Department of Emergency Medicine, Rush University Medical Center, United States of America b Department of Emergency Medicine, Brooke Army Medical Center, United States of America article info abstract Article history: The novel coronavirus disease of 2019 (COVID-19) is associated with significant morbidity and mortality. While Received 9 May 2020 much of the focus has been on the cardiac and pulmonary complications, there are several important dermato- Accepted 3 June 2020 logic components that clinicians must be aware of. Available online xxxx Objective: This brief report summarizes the dermatologic manifestations and complications associated with COVID-19 with an emphasis on Emergency Medicine clinicians. Keywords: COVID-19 Discussion: Dermatologic manifestations of COVID-19 are increasingly recognized within the literature. The pri- fi SARS-CoV-2 mary etiologies include vasculitis versus direct viral involvement. There are several types of skin ndings de- Coronavirus scribed in association with COVID-19. These include maculopapular rashes, urticaria, vesicles, petechiae, Dermatology purpura, chilblains, livedo racemosa, and distal limb ischemia. While most of these dermatologic findings are Skin self-resolving, they can help increase one's suspicion for COVID-19. Emergency medicine Conclusion: It is important to be aware of the dermatologic manifestations and complications of COVID-19. Knowledge of the components is important to help identify potential COVID-19 patients and properly treat complications. © 2020 Elsevier Inc.
    [Show full text]
  • Dermatological Findings in Common Rheumatologic Diseases in Children
    Available online at www.medicinescience.org Medicine Science ORIGINAL RESEARCH International Medical Journal Medicine Science 2019; ( ): Dermatological findings in common rheumatologic diseases in children 1Melike Kibar Ozturk ORCID:0000-0002-5757-8247 1Ilkin Zindanci ORCID:0000-0003-4354-9899 2Betul Sozeri ORCID:0000-0003-0358-6409 1Umraniye Training and Research Hospital, Department of Dermatology, Istanbul, Turkey. 2Umraniye Training and Research Hospital, Department of Child Rheumatology, Istanbul, Turkey Received 01 November 2018; Accepted 19 November 2018 Available online 21.01.2019 with doi:10.5455/medscience.2018.07.8966 Copyright © 2019 by authors and Medicine Science Publishing Inc. Abstract The aim of this study is to outline the common dermatological findings in pediatric rheumatologic diseases. A total of 45 patients, nineteen with juvenile idiopathic arthritis (JIA), eight with Familial Mediterranean Fever (FMF), six with scleroderma (SSc), seven with systemic lupus erythematosus (SLE), and five with dermatomyositis (DM) were included. Control group for JIA consisted of randomly chosen 19 healthy subjects of the same age and gender. The age, sex, duration of disease, site and type of lesions on skin, nails and scalp and systemic drug use were recorded. χ2 test was used. The most common skin findings in patients with psoriatic JIA were flexural psoriatic lesions, the most common nail findings were periungual desquamation and distal onycholysis, while the most common scalp findings were erythema and scaling. The most common skin finding in patients with oligoarthritis was photosensitivity, while the most common nail finding was periungual erythema, and the most common scalp findings were erythema and scaling. We saw urticarial rash, dermatographism, nail pitting and telogen effluvium in one patient with systemic arthritis; and photosensitivity, livedo reticularis and periungual erythema in another patient with RF-negative polyarthritis.
    [Show full text]
  • Apo-Ropinirole
    New Zealand Data Sheet APO-ROPINIROLE 1. PRODUCT NAME APO-ROPINIROLE 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg and 5mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ropinirole hydrochloride 0.25mg Ropinirole hydrochloride 0.5mg Ropinirole hydrochloride 1mg Ropinirole hydrochloride 2mg Ropinirole hydrochloride 3mg Ropinirole hydrochloride 4mg Ropinirole hydrochloride 5mg Excipient(s) with known effect Contains lactose. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM APO-ROPINIROLE is available as oral, film coated tablets in the following strengths: APO-ROPINIROLE 0.25mg tablets are white, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “.25” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 0.5mg tablets are yellow, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “.5” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 1mg tablets are green, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “1” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 2mg tablets are pink, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “2” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 3mg tablets are purple, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “3” on one side and “APO’ on the other side. Each tablet typically weighs about 153mg. APO-ROPINIROLE 4mg tablets are pale brown, pentagonal, biconvex film-coated tablet identified by an engraved “ROP” over “4” on one side and “APO’ on the other side.
    [Show full text]
  • Review Cutaneous Patterns Are Often the Only Clue to a a R T I C L E Complex Underlying Vascular Pathology
    pp11 - 46 ABstract Review Cutaneous patterns are often the only clue to a A R T I C L E complex underlying vascular pathology. Reticulate pattern is probably one of the most important DERMATOLOGICAL dermatological signs of venous or arterial pathology involving the cutaneous microvasculature and its MANIFESTATIONS OF VENOUS presence may be the only sign of an important underlying pathology. Vascular malformations such DISEASE. PART II: Reticulate as cutis marmorata congenita telangiectasia, benign forms of livedo reticularis, and sinister conditions eruptions such as Sneddon’s syndrome can all present with a reticulate eruption. The literature dealing with this KUROSH PARSI MBBS, MSc (Med), FACP, FACD subject is confusing and full of inaccuracies. Terms Departments of Dermatology, St. Vincent’s Hospital & such as livedo reticularis, livedo racemosa, cutis Sydney Children’s Hospital, Sydney, Australia marmorata and retiform purpura have all been used to describe the same or entirely different conditions. To our knowledge, there are no published systematic reviews of reticulate eruptions in the medical Introduction literature. he reticulate pattern is probably one of the most This article is the second in a series of papers important dermatological signs that signifies the describing the dermatological manifestations of involvement of the underlying vascular networks venous disease. Given the wide scope of phlebology T and its overlap with many other specialties, this review and the cutaneous vasculature. It is seen in benign forms was divided into multiple instalments. We dedicated of livedo reticularis and in more sinister conditions such this instalment to demystifying the reticulate as Sneddon’s syndrome. There is considerable confusion pattern.
    [Show full text]
  • Edema II, Clinical Significance
    EDEMA II CLINICAL SIGNIFICANCE F. A. LeFEVRE, M.D., R. H. McDONALD, M.D., AND A. C. CORCORAN, M.D. It is the purpose of this paper to outline the clinical syndromes in which edema significantly appears, to discuss their differentiation, and to comment on the changes to which edema itself may give rise. The frequency with which edema occurs indicates the variety of its origins. Its physiologic bases have been reviewed in a former paper.1 Conditions in which edema commonly appears are summarized in Table 1. Although clinical edema usually involves more than one physiologic mechanism, it is not difficult to determine the predominant disturbance. Table 2 illustrates the physiologic mechanisms of clinical edema. Physiologically, edema is an excessive accumulation of interstitial fluid. Clinically, it may be latent or manifest, and, by its nature, localized or generalizing. These terms, with the exception of generalizing, have been defined, and may be accepted. By generalizing edema is meant a condi- tion in which edema is at first local in its appearance, but in which, as the process extends, edema will become general, causing anasarca. The degree of edema in any area is limited by tissue tension and the sites of its first appearance and later spread are partly determined by gravity. CARDIAC EDEMA Generalizing edema is an early manifestation of cardiac failure. It is usually considered to be evidence of inadequacy of the right ventricu- lar musculature (back pressure theory). Peripheral edema may be accompanied by pulmonary edema in cases where there is simultaneous left ventricular failure. Actually, the genesis of cardiac edema may depend more on sodium retention2,3'4 due to "forward cardiac failure" and renal constriction than on venous back pressure alone.
    [Show full text]
  • A Resident's Guide to Pediatric Rheumatology
    A RESIDENT’S GUIDE TO PEDIATRIC RHEUMATOLOGY 4th Revised Edition - 2019 A RESIDENT’S GUIDE TO PEDIATRIC RHEUMATOLOGY This guide is intended to provide a brief introduction to basic topics in pediatric rheumatology. Each topic is accompanied by at least one up-to-date reference that will allow you to explore the topic in greater depth. In addition, a list of several excellent textbooks and other resources for you to use to expand your knowledge is found in the Appendix. We are interested in your feedback on the guide! If you have comments or questions, please feel free to contact us via email at [email protected]. Supervising Editors: Dr. Ronald M. Laxer, SickKids Hospital, University of Toronto Dr. Tania Cellucci, McMaster Children’s Hospital, McMaster University Dr. Evelyn Rozenblyum, St. Michael’s Hospital, University of Toronto Section Editors: Dr. Michelle Batthish, McMaster Children’s Hospital, McMaster University Dr. Roberta Berard, Children’s Hospital – London Health Sciences Centre, Western University Dr. Liane Heale, McMaster Children’s Hospital, McMaster University Dr. Clare Hutchinson, North York General Hospital, University of Toronto Dr. Mehul Jariwala, Royal University Hospital, University of Saskatchewan Dr. Lillian Lim, Stollery Children’s Hospital, University of Alberta Dr. Nadia Luca, Alberta Children’s Hospital, University of Calgary Dr. Dax Rumsey, Stollery Children’s Hospital, University of Alberta Dr. Gordon Soon, North York General Hospital and SickKids Hospital Northern Clinic in Sudbury, University
    [Show full text]
  • Managing Hyponatremia in Patients with Syndrome of Inappropriate Antidiuretic Hormone Secretion
    REVIEW Managing Hyponatremia in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Joseph G. Verbalis, MD Division of Endocrinology and Metabolism, Department of Medicine, Georgetown University Medical Center, Washington DC. J.G. Verbalis received an honorarium funded by an unrestricted educational grant from Otsuka America Pharmaceuticals, Inc., for time and expertise spent in the composition of this article. No editorial assistance was provided. No other conflicts exist. This review will address the management of hyponatremia caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in hospitalized patients. To do so requires an understanding of the pathogenesis and diagnosis of SIADH, as well as currently available treatment options. The review will be structured as responses to a series of questions, followed by a presentation of an algorithm for determining the most appropriate treatments for individual patients with SIADH based on their presenting symptoms. Journal of Hospital Medicine 2010;5:S18–S26. VC 2010 Society of Hospital Medicine. Why is SIADH Important to Hospitalists? What Causes Hyponatremia in Patients with SIADH? Disorders of body fluids, and particularly hyponatremia, are Hyponatremia can be caused by 1 of 2 potential disruptions among the most commonly encountered problems in clinical in fluid balance: dilution from retained water, or depletion medicine, affecting up to 30% of hospitalized patients. In a from electrolyte losses in excess of water. Dilutional hypo- study of 303,577 laboratory samples collected from 120,137 natremias are associated with either a normal (euvolemic) patients, the prevalence of hyponatremia (serum [Naþ] <135 or an increased (hypervolemic) extracellular fluid (ECF) vol- mmol/L) on initial presentation to a healthcare provider was ume, whereas depletional hyponatremias generally are asso- 28.2% among those treated in an acute hospital care setting, ciated with a decreased ECF volume (hypovolemic).
    [Show full text]
  • Neuroenhancement in Healthy Adults, Part I: Pharmaceutical
    l Rese ca arc ni h li & C f B o i o l e Journal of a t h n Fond et al., J Clinic Res Bioeth 2015, 6:2 r i c u s o J DOI: 10.4172/2155-9627.1000213 ISSN: 2155-9627 Clinical Research & Bioethics Review Article Open Access Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review Fond G1,2*, Micoulaud-Franchi JA3, Macgregor A2, Richieri R3,4, Miot S5,6, Lopez R2, Abbar M7, Lancon C3 and Repantis D8 1Université Paris Est-Créteil, Psychiatry and Addiction Pole University Hospitals Henri Mondor, Inserm U955, Eq 15 Psychiatric Genetics, DHU Pe-psy, FondaMental Foundation, Scientific Cooperation Foundation Mental Health, National Network of Schizophrenia Expert Centers, F-94000, France 2Inserm 1061, University Psychiatry Service, University of Montpellier 1, CHU Montpellier F-34000, France 3POLE Academic Psychiatry, CHU Sainte-Marguerite, F-13274 Marseille, Cedex 09, France 4 Public Health Laboratory, Faculty of Medicine, EA 3279, F-13385 Marseille, Cedex 05, France 5Inserm U1061, Idiopathic Hypersomnia Narcolepsy National Reference Centre, Unit of sleep disorders, University of Montpellier 1, CHU Montpellier F-34000, Paris, France 6Inserm U952, CNRS UMR 7224, Pierre and Marie Curie University, F-75000, Paris, France 7CHU Carémeau, University of Nîmes, Nîmes, F-31000, France 8Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany *Corresponding author: Dr. Guillaume Fond, Pole de Psychiatrie, Hôpital A. Chenevier, 40 rue de Mesly, Créteil F-94010, France, Tel: (33)178682372; Fax: (33)178682381; E-mail: [email protected] Received date: January 06, 2015, Accepted date: February 23, 2015, Published date: February 28, 2015 Copyright: © 2015 Fond G, et al.
    [Show full text]
  • COVID-19 Mrna Pfizer- Biontech Vaccine Analysis Print
    COVID-19 mRNA Pfizer- BioNTech Vaccine Analysis Print All UK spontaneous reports received between 9/12/20 and 22/09/21 for mRNA Pfizer/BioNTech vaccine. A report of a suspected ADR to the Yellow Card scheme does not necessarily mean that it was caused by the vaccine, only that the reporter has a suspicion it may have. Underlying or previously undiagnosed illness unrelated to vaccination can also be factors in such reports. The relative number and nature of reports should therefore not be used to compare the safety of the different vaccines. All reports are kept under continual review in order to identify possible new risks. Report Run Date: 24-Sep-2021, Page 1 Case Series Drug Analysis Print Name: COVID-19 mRNA Pfizer- BioNTech vaccine analysis print Report Run Date: 24-Sep-2021 Data Lock Date: 22-Sep-2021 18:30:09 MedDRA Version: MedDRA 24.0 Reaction Name Total Fatal Blood disorders Anaemia deficiencies Anaemia folate deficiency 1 0 Anaemia vitamin B12 deficiency 2 0 Deficiency anaemia 1 0 Iron deficiency anaemia 6 0 Anaemias NEC Anaemia 97 0 Anaemia macrocytic 1 0 Anaemia megaloblastic 1 0 Autoimmune anaemia 2 0 Blood loss anaemia 1 0 Microcytic anaemia 1 0 Anaemias haemolytic NEC Coombs negative haemolytic anaemia 1 0 Haemolytic anaemia 6 0 Anaemias haemolytic immune Autoimmune haemolytic anaemia 9 0 Anaemias haemolytic mechanical factor Microangiopathic haemolytic anaemia 1 0 Bleeding tendencies Haemorrhagic diathesis 1 0 Increased tendency to bruise 35 0 Spontaneous haematoma 2 0 Coagulation factor deficiencies Acquired haemophilia
    [Show full text]
  • Pramipexole V2.1 Last Reviewed: 22/04/2021 Review Date: 22/04/2024
    Pramipexole V2.1 Last reviewed: 22/04/2021 Review date: 22/04/2024 Pramipexole Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers CLINICAL INFORMATION Key points/interactions Nausea is a common early side effect but usually responds to domperidone (10mg tds, or lowest effective dose – see MHRA advice) Ropinirole MR is first line dopamine agonist. Pramipexole MR should be reserved for patients in whom this is not suitable- see formulary. Dopamine agonists may cause compulsive/addictive behaviours such as gambling, compulsive shopping and hyper sexuality. Patients rarely recognise such changes as side effects and rarely report them unless specifically asked. Licensed Indications Treatment of idiopathic Parkinson's disease. Pramipexole may be used alone (without levodopa) or in combination with levodopa throughout the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on-off” fluctuations). Therapeutic Summary As per the licensed indication. NICE recommendations for the use of Pramipexole in Parkinson’s disease are: Consider a choice of dopamine agonists, levodopa or monoamine oxidase B (MAO-B) inhibitors for people in the early stages of Parkinson's disease whose motor symptoms do not impact their quality of life. Do not offer ergot-derived dopamine agonists as first-line treatment for Parkinson's disease. Offer a choice of dopamine agonists, MAO-B inhibitors or catechol-O-methyltransferase (COMT)
    [Show full text]
  • Integrated Approaches for Genome-Wide Interrogation of The
    MINIREVIEW THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 290, NO. 32, pp. 19471–19477, August 7, 2015 © 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A. 5-HT serotonin receptor agonism have long been docu- Integrated Approaches for 2B mented to induce severe, life-threatening valvular heart disease Genome-wide Interrogation of (6–8). Indeed, based on the potent 5-HT2B agonist activity of the Druggable Non-olfactory G certain ergot derivatives used in treating Parkinson disease and migraine headaches (e.g. pergolide, cabergoline, and dihydroer- Protein-coupled Receptor gotamine), we correctly predicted that these medications * would also induce valvular heart disease (7, 8). Two of these Superfamily drugs (pergolide and cabergoline) were withdrawn from the Published, JBC Papers in Press, June 22, 2015, DOI 10.1074/jbc.R115.654764 Bryan L. Roth1 and Wesley K. Kroeze international market following large-scale trials demonstrating From the Department of Pharmacology, University of North Carolina their life-threating side effects (8, 9). In follow-up studies, we Chapel Hill School of Medicine, Chapel Hill, North Carolina 27514 surveyed 2200 FDA-approved and investigational medications, finding that 27 had potentially significant 5-HT2B agonism, of G-protein-coupled receptors (GPCRs) are frequent and fruit- which 6 are currently FDA-approved (guanfacine, quinidine, ful targets for drug discovery and development, as well as being xylometazoline, oxymetazoline, fenoldopam, and ropinirole) off-targets for the side effects of a variety of medications. Much (10). Interestingly, of the 2200 drugs screened, around 30% dis- of the druggable non-olfactory human GPCR-ome remains played significant 5-HT2B antagonist activity (10), indicating under-interrogated, and we present here various approaches that 5-HT2B receptors represent a “promiscuous target” for that we and others have used to shine light into these previously approved and candidate medications.
    [Show full text]
  • Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders
    biomolecules Review Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders Béla Kiss 1, István Laszlovszky 2, Balázs Krámos 3, András Visegrády 1, Amrita Bobok 1, György Lévay 1, Balázs Lendvai 1 and Viktor Román 1,* 1 Pharmacological and Drug Safety Research, Gedeon Richter Plc., 1103 Budapest, Hungary; [email protected] (B.K.); [email protected] (A.V.); [email protected] (A.B.); [email protected] (G.L.); [email protected] (B.L.) 2 Medical Division, Gedeon Richter Plc., 1103 Budapest, Hungary; [email protected] 3 Spectroscopic Research Department, Gedeon Richter Plc., 1103 Budapest, Hungary; [email protected] * Correspondence: [email protected]; Tel.: +36-1-432-6131; Fax: +36-1-889-8400 Abstract: Dopamine (DA), as one of the major neurotransmitters in the central nervous system (CNS) and periphery, exerts its actions through five types of receptors which belong to two major subfamilies such as D1-like (i.e., D1 and D5 receptors) and D2-like (i.e., D2, D3 and D4) receptors. Dopamine D3 receptor (D3R) was cloned 30 years ago, and its distribution in the CNS and in the periphery, molecular structure, cellular signaling mechanisms have been largely explored. Involvement of D3Rs has been recognized in several CNS functions such as movement control, cognition, learning, reward, emotional regulation and social behavior. D3Rs have become a promising target of drug research and great efforts have been made to obtain high affinity ligands (selective agonists, partial agonists and antagonists) in order to elucidate D3R functions. There has been a strong drive behind the efforts to find drug-like compounds with high affinity and selectivity and various functionality for D3Rs in the hope that they would have potential treatment options in CNS diseases such as schizophrenia, drug abuse, Parkinson’s disease, depression, and restless leg syndrome.
    [Show full text]